$0.56
+0.06 (+11.52%)
Open$0.51
Previous Close$0.51
Day High$0.57
Day Low$0.50
52W High$43.60
52W Low$20.48
Volume—
Avg Volume426.7K
Market Cap22.89M
P/E Ratio—
EPS$-0.11
SectorBiotechnology
Analyst Ratings
Sell
10 analysts
Price Target
+8,683.7% upside
Current
$0.56
$0.56
Target
$49.47
$49.47
$36.23
$49.47 avg
$53.77
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 9.99M | 9.03M | 9.73M |
| Net Income | 2.33M | 1.99M | 2.35M |
| Profit Margin | 23.4% | 22.0% | 24.2% |
| EBITDA | 3.37M | 3.04M | 3.38M |
| Free Cash Flow | 2.45M | 1.40M | 2.01M |
| Rev Growth | +15.3% | +1.4% | +15.7% |
| Debt/Equity | 0.53 | 0.61 | 0.59 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |